You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬方發展(000638.SZ):控股子公司受託管理CHO細胞重組乙肝疫苗業務
格隆匯 04-19 12:01

格隆匯4月19日丨萬方發展(000638.SZ)公佈,2021年3月9日,公司控股子公司吉林萬方百奧生物科技有限公司簡稱“萬方百奧”)與北京富亞東投資管理有限公司(簡稱“富亞東”)、北京亞東生物製藥(安國)有限公司(簡稱“亞東生物(安國)”)簽訂了《股權轉讓框架協議》,根據股權轉讓框架協議約定,萬方百奧擬收購富亞東持有的亞東生物(安國)不低於15%的股權,首付款為人民幣3000萬元。

亞東生物(安國)目前擁有重組乙型肝炎疫苗(CHO細胞)藥品文號(兩個規格:國藥準字 S19990072(10μ g/0.5ml)、國藥準字 S20010009(20μ g/1.0ml)),分別用於新生兒(一類)和母嬰阻斷(二類)的乙肝免疫治療,目前兩個文號正在進行現場認證前的準備工作。

2021年4月16日,亞東生物(安國)與萬方百奧簽訂《委託管理協議書》,亞東生物(安國)將涉及其疫苗業務的生產經營、管理權全部委託於萬方百奧行使,委託管理期限為兩年,自2021年3月1日起至2023年2月28日止。

公司表示,該次受託管理將充分發揮萬方百奧的專業特長,主導推進兩個乙肝疫苗儘早批簽發上市,併為後續取得亞東生物(安國)的控制權做好鋪墊。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account